FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169094018> ?p ?o ?g. }

• W3169094018 endingPage "839" @default.
• W3169094018 startingPage "839" @default.
• W3169094018 abstract "Clinical trials of glaucoma therapies focused on protecting the optic nerve have required large sample sizes and lengthy follow-up to detect clinically relevant change due to its slow rate of progression. Whether shorter trials may be possible with more frequent testing and use of rate of change as the end point warrants further investigation.To describe the design for the Short-term Assessment of Glaucoma Progression (STAGE) model and provide guidance on sample size and power calculations for shorter clinical trials.A cohort study of patients with mild, moderate, or advanced open-angle glaucoma recruited from the Diagnostic Innovations in Glaucoma Study at the University of California, San Diego. Enrollment began in May 2012 with follow-up for every 3 months for 2 years after baseline examination. Follow-up was concluded in September 2016. Data were analyzed from July 2019 to January 2021. Visual fields (VF) and optic coherence tomography (OCT) scans were obtained at baseline and for 2 years with visits every 3 months.Glaucoma was defined as glaucomatous appearing optic discs classified by disc photographs in at least 1 eye and/or repeatable VF damage at baseline.Longitudinal rates of change in retinal nerve fiber layer (RNFL) thickness and VF mean deviation (MD) are estimated in study designs of varying length and observation frequency. Power calculations as functions of study length, observation frequency, and sample size were performed.In a total referred sample of 97 patients with mild, moderate, or advanced glaucoma (mean [SD] age, 69 [11.4] years; 50 [51.5%] were female; 19 [19.6%]), over the 2-year follow-up, the mean VF 24-2 MD slope was -0.32 dB/y (95% CI, -0.43 to -0.21 dB/y) and the mean RNFL thickness slope was -0.54 μm/y (95% CI, -0.75 to -0.32 μm/y). Sufficient power (80%) to detect similar group differences in the rate of change in both outcomes was attained with total follow-up between 18 months and 2 years and fewer than 300 total participants.In this cohort study, results from the STAGE model with reduction of the rate of progression as the end point, frequent testing, and a moderate effect size, suggest that clinical trials to test efficacy of glaucoma therapy can be completed within 18 months of follow-up and with fewer than 300 participants." @default.
• W3169094018 created "2021-06-22" @default.
• W3169094018 creator A5004613074 @default.
• W3169094018 creator A5009959838 @default.
• W3169094018 creator A5021685813 @default.
• W3169094018 creator A5043994887 @default.
• W3169094018 creator A5046413569 @default.
• W3169094018 creator A5053225513 @default.
• W3169094018 creator A5054251154 @default.
• W3169094018 creator A5057658167 @default.
• W3169094018 creator A5063363976 @default.
• W3169094018 creator A5075198015 @default.
• W3169094018 creator A5086142745 @default.
• W3169094018 creator A5089620669 @default.
• W3169094018 date "2021-08-01" @default.
• W3169094018 modified "2023-09-27" @default.
• W3169094018 title "Estimated Utility of the Short-term Assessment of Glaucoma Progression Model in Clinical Practice" @default.
• W3169094018 cites W1965921725 @default.
• W3169094018 cites W1970913176 @default.
• W3169094018 cites W1971485236 @default.
• W3169094018 cites W1972747837 @default.
• W3169094018 cites W1974545726 @default.
• W3169094018 cites W1989239239 @default.
• W3169094018 cites W1994649391 @default.
• W3169094018 cites W2000670481 @default.
• W3169094018 cites W2007419530 @default.
• W3169094018 cites W2007602673 @default.
• W3169094018 cites W2008281905 @default.
• W3169094018 cites W2026582925 @default.
• W3169094018 cites W2030153948 @default.
• W3169094018 cites W2033547694 @default.
• W3169094018 cites W2034742711 @default.
• W3169094018 cites W2041817825 @default.
• W3169094018 cites W2043991271 @default.
• W3169094018 cites W2047126828 @default.
• W3169094018 cites W2064553894 @default.
• W3169094018 cites W2065289190 @default.
• W3169094018 cites W2067107925 @default.
• W3169094018 cites W2068005245 @default.
• W3169094018 cites W2087128272 @default.
• W3169094018 cites W2109706077 @default.
• W3169094018 cites W2112566344 @default.
• W3169094018 cites W2123411566 @default.
• W3169094018 cites W2128959641 @default.
• W3169094018 cites W2147379623 @default.
• W3169094018 cites W234332937 @default.
• W3169094018 cites W2521776509 @default.
• W3169094018 cites W2592231357 @default.
• W3169094018 cites W2596983421 @default.
• W3169094018 cites W2743253227 @default.
• W3169094018 cites W2770233253 @default.
• W3169094018 cites W2806767760 @default.
• W3169094018 cites W2887133221 @default.
• W3169094018 cites W2910439267 @default.
• W3169094018 cites W2921253323 @default.
• W3169094018 cites W4232819055 @default.
• W3169094018 cites W4234398407 @default.
• W3169094018 cites W4254209618 @default.
• W3169094018 cites W4292528167 @default.
• W3169094018 doi "https://doi.org/10.1001/jamaophthalmol.2021.1812" @default.
• W3169094018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8193543" @default.
• W3169094018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34110362" @default.
• W3169094018 hasPublicationYear "2021" @default.
• W3169094018 type Work @default.
• W3169094018 sameAs 3169094018 @default.
• W3169094018 citedByCount "5" @default.
• W3169094018 countsByYear W31690940182022 @default.
• W3169094018 countsByYear W31690940182023 @default.
• W3169094018 crossrefType "journal-article" @default.
• W3169094018 hasAuthorship W3169094018A5004613074 @default.
• W3169094018 hasAuthorship W3169094018A5009959838 @default.
• W3169094018 hasAuthorship W3169094018A5021685813 @default.
• W3169094018 hasAuthorship W3169094018A5043994887 @default.
• W3169094018 hasAuthorship W3169094018A5046413569 @default.
• W3169094018 hasAuthorship W3169094018A5053225513 @default.
• W3169094018 hasAuthorship W3169094018A5054251154 @default.
• W3169094018 hasAuthorship W3169094018A5057658167 @default.
• W3169094018 hasAuthorship W3169094018A5063363976 @default.
• W3169094018 hasAuthorship W3169094018A5075198015 @default.
• W3169094018 hasAuthorship W3169094018A5086142745 @default.
• W3169094018 hasAuthorship W3169094018A5089620669 @default.
• W3169094018 hasBestOaLocation W31690940182 @default.
• W3169094018 hasConcept C105795698 @default.
• W3169094018 hasConcept C118487528 @default.
• W3169094018 hasConcept C126322002 @default.
• W3169094018 hasConcept C129848803 @default.
• W3169094018 hasConcept C2778527774 @default.
• W3169094018 hasConcept C2779735895 @default.
• W3169094018 hasConcept C2780592520 @default.
• W3169094018 hasConcept C2780837183 @default.
• W3169094018 hasConcept C33923547 @default.
• W3169094018 hasConcept C535046627 @default.
• W3169094018 hasConcept C71924100 @default.
• W3169094018 hasConceptScore W3169094018C105795698 @default.
• W3169094018 hasConceptScore W3169094018C118487528 @default.
• W3169094018 hasConceptScore W3169094018C126322002 @default.
• W3169094018 hasConceptScore W3169094018C129848803 @default.
• W3169094018 hasConceptScore W3169094018C2778527774 @default.

• next